MicroED Structures of Fluticasone Furoate and Fluticasone Propionate Provide New Insights into Their Function

被引:0
|
作者
Lin, Jieye [1 ]
Unge, Johan [2 ]
Gonen, Tamir [1 ]
机构
[1] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA
[2] Umea Univ, Dept Chem, Umea 90178, Sweden
基金
美国国家卫生研究院;
关键词
GLUCOCORTICOID-RECEPTOR; LIGAND-BINDING; TRANSLOCATION; PERFORMANCE; ENERGIES; INHALER; ATOMS; SET;
D O I
10.1021/acs.cgd.4c01683
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The detailed understanding of the conformational pathway of fluticasone, a widely prescribed medicine for allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD), from formulation to its protein-bound state, has been limited due to a lack of access to its high-resolution structures. The three-dimensional (3D) structure of fluticasone furoate 1 remains unpublished, and the deposited structure of fluticasone propionate 2 could be further refined due to refinement against new data. We applied microcrystal electron diffraction (MicroED) to determine the 3D structures of 1 and 2 in their solid states. The preferred geometries in solution were predicted by using density functional theory (DFT) calculations. A comparative analysis of the structures of 1 and 2 across three states (in solid state, in solution, and protein-bound conformation) revealed the course of the conformational changes during the entire transition. Potential energy plots were calculated for the most dynamic bonds, uncovering their rotational barriers. This study underscores the combined use of MicroED and DFT calculations to provide a comprehensive understanding of conformational and energy changes during drug administration. The quantitative comparison also highlights the subtle structural differences that may lead to significant changes in the pharmaceutical properties.
引用
收藏
页码:1588 / 1596
页数:9
相关论文
共 50 条
  • [1] Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate
    Daley-Yates, Peter T.
    Deans, Amanda
    Mehta, Rashmi
    Sousa, Ana R.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2022, 77
  • [2] Fluticasone furoate/fluticasone propionate - different drugs with different properties
    Biggadike, Keith
    CLINICAL RESPIRATORY JOURNAL, 2011, 5 (03): : 183 - 184
  • [3] Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
    Kariyawasam, Harsha H.
    Scadding, Glenis K.
    JOURNAL OF ASTHMA AND ALLERGY, 2010, 3 : 19 - 28
  • [4] Comparison of fluticasone furoate and fluticasone propionate for the treatment of Japanese cedar pollinosis
    Okubo, Kimihiro
    Nakashima, Mitsuyoshi
    Miyake, Noboru
    Komatsubara, Masaki
    Okuda, Minoru
    ALLERGY AND ASTHMA PROCEEDINGS, 2009, 30 (01) : 84 - 94
  • [5] Fluticasone furoate/vilanterol versus fluticasone propionate in patients with asthma and exercise-induced bronchoconstriction
    Martin, Neil
    Weiler, John M.
    Pearlman, David
    Jacques, Loretta
    Nunn, Carol
    Forth, Richard
    West, Sarah
    Dunn, Karen
    O'Byrne, Paul M.
    JOURNAL OF ASTHMA, 2020, 57 (04) : 431 - 440
  • [6] Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays
    Daley-Yates, PT
    Kunka, RL
    Yin, Y
    Andrews, SM
    Callejas, S
    Ng, C
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 60 (04) : 265 - 268
  • [7] Mometasone furoate is a less specific glucocorticoid than fluticasone propionate
    Austin, RJH
    Maschera, B
    Walker, A
    Fairbairn, L
    Meldrum, E
    Farrow, SN
    Uings, IJ
    EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (06) : 1386 - 1392
  • [8] A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate
    Crim, C
    Pierre, LN
    Daley-Yates, PT
    CLINICAL THERAPEUTICS, 2001, 23 (09) : 1339 - 1354
  • [9] Fluticasone propionate and mometasone furoate have equivalent transcriptional potencies
    Roumestan, C
    Henriquet, C
    Bousquet, J
    Mathieu, M
    CLINICAL AND EXPERIMENTAL ALLERGY, 2003, 33 (07): : 895 - 901
  • [10] Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays
    P. T. Daley-Yates
    R. L. Kunka
    Y. Yin
    S. M. Andrews
    S. Callejas
    C. Ng
    European Journal of Clinical Pharmacology, 2004, 60 : 265 - 268